H. Lundbeck AS (HLUBF) reports a 21% revenue increase, raises full-year guidance, and showcases significant progress in innovation and market strategies.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Teva's CEO, Richard Francis. After a hiatus of almost a decade, Teva has made a pipeline-building acquisition, buying Emalex Biosciences and its candidate therapy for Tourette's syndrome for up to ...

Good morning, and welcome to the Viatris First Quarter 2026 Earnings Call. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conference over to Bill ...

Japanese pharma group Otsuka has led a $10 million first-round financing of GrayMatters Health, an Israeli company developing a digital health approach to the management of mental illness. Otsuka ...

Viatris’ latest earnings call struck a cautiously upbeat tone, as management emphasized steady revenue growth, expanding profitability and strong momentum in China alongside a deepening pipeline and ...

NEW YORK, NY / ACCESS Newswire / May 19, 2026 / Protagenic Therapeutics, Inc. (OTCQB:PTIX), a clinical-stage biopharmaceutical company developing novel peptide-based therapies for stress-related neuro ...

Teva Pharmaceuticals will acquire neuroscience specialist, Emalex – a move which Teva executive, Evan Lippman, says effectively complements the company’s wider “pivot to growth” strategy. Through this ...

Teva’s VP of business development, Evan Lippman talks Pharmaceutical Technology through Teva’s dealmaking and future growth strategy. Credit: Jonathan Weiss / Shutterstock.com. Teva Pharmaceuticals ...

Introduction Antipsychotic medications are commonly prescribed off-label in acutely ill patients for non-psychiatric clinical indications such as delirium or insomnia. New prescription initiation of ...